Editing Pemetrexed (section)

===Carboplatin===
Pemetrexed is also recommended in combination with [[carboplatin]] and [[pembrolizumab]] for the first-line treatment of advanced non-small cell lung cancer.<ref>{{cite web | vauthors = Ettinger DS, etal | work = NCCN Clinical Practice Guidelines in Oncology | title = Non-small Cell Lung Cancer V.1.2007 | publisher =  National Comprehensive Cancer Network (NCCN) | url = https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf | archive-url = https://web.archive.org/web/20070323012050/https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf | archive-date = 23 March 2007 }}</ref><ref>{{cite journal | vauthors = Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC | display-authors = 6 | title = Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer | journal = The New England Journal of Medicine | volume = 378 | issue = 22 | pages = 2078–2092 | date = May 2018 | pmid = 29658856 | doi = 10.1056/NEJMoa1801005 | collaboration = KEYNOTE-189 Investigators | doi-access = free | hdl = 10138/298862 | hdl-access = free }}</ref> However, the relative efficacy or toxicity of pemetrexed-cisplatin versus pemetrexed-carboplatin has not been established beyond what is generally thought about cisplatin or carboplatin doublet drug therapy.<ref>{{cite journal | vauthors = Azzoli CG, Kris MG, Pfister DG | title = Cisplatin versus carboplatin for patients with metastatic non-small-cell lung cancer--an old rivalry renewed | journal = Journal of the National Cancer Institute | volume = 99 | issue = 11 | pages = 828–829 | date = June 2007 | pmid = 17551137 | doi = 10.1093/jnci/djk222 | doi-access = free }}</ref>